[Acquired deficiencies in antithrombin III and C protein during treatment with L-asparaginase].
Fourteen children treated by L-Asparaginase for acute lymphoblastic leukemia had sequential coagulation studies performed including cephalin-kaolin time, Quick time, fibrinogen, factors II, VII + X and V, as well as antithrombin III and protein C, the major coagulation inhibitors. A severe antithrombin III and protein C deficiency was observed during therapy, with a coexisting hypocoagulability. This equilibrium partially explains the lack of thrombo-embolic phenomena in these children, despite the risk factors present. Although no substitutive therapy was instituted in these cases, their use in high-risk cases is discussed.
D000293:Adolescent; D020152:Antithrombin III Deficiency; D001215:Asparaginase / Q000009:adverse effects* / Q000627:therapeutic use; D002352:Carrier Proteins / Q000172:deficiency*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D008297:Male
D002352:Carrier Proteins; C020723:citrate-binding transport protein; D001215:Asparaginase
Déficits acquis en antithrombine III et en protéine C au cours du traitement par la L-asparaginase.